Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Centogene receives Nasdaq delisting notice for non-compliance with market value requirement.
Centogene, a life sciences firm focusing on rare and neurodegenerative diseases, received a notice of delisting from Nasdaq due to non-compliance with the $15m Market Value of Publicly Held Shares requirement.
The company plans to request a hearing to address the issue and prevent suspension or delisting.
Despite the notice, Centogene will continue working with strategic partners to accelerate drug discovery, development, and commercialization.
3 Articles
Centogene recibe una notificación de exclusión de Nasdaq por incumplimiento del requisito de valor de mercado.